Introduction: The development of the first molecular targeted therapies for neuroendocrine tumors (NET) was a milestone in the treatment of patient. Nevertheless, these therapies eventually fail and patients become resistant to the treatment. One way of escaping this dilemma might be the combination of targeted drugs to prevent resistance development.
Aim(s): The aim of the study was to assess the potency and synergistic effects of different targeted therapies in NET.
Materials and methods: We studied the effect of mono- and combination therapies of the PI3K inhibitor BYL719, Hsp90 inhibitor AUY922 and mTOR inhibitor Everolimus in the human pancreatic NET cell lines BON, QGP-1 and NT-3. Signal pathway activation was analyzed by western blot.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Joerg Schrader
To read results and conclusion, please login ...
Further abstracts you may be interested in